- The Washington Times - Wednesday, September 14, 2005

ATLANTIC CITY, N.J. (AP) — A product liability case blaming a man’s heart attack on the painkiller Vioxx started yesterday, with his attorney telling jurors the drug’s maker put profits over safety. Manufacturer Merck & Co. Inc. asserted there were other causes for the heart attack.

Chris Seeger, lead attorney for 60-year-old Idaho postal worker Frederick “Mike” Humeston, said Mr. Humeston was a healthy, active Vietnam veteran who enjoyed hiking when he was stricken two months after his doctor prescribed Vioxx to relieve pain from a war injury.

Merck knew the drug had links to increased incidence of heart attacks long before Mr. Humeston’s Sept. 18, 2001, heart attack but didn’t disclose it, Mr. Seeger said in his 90-minute opening statement.

“Did they issue a ‘Dear Doctor’ letter? No. Did they warn patients? No, they didn’t do that either. Did they change the [warning] label? No, they didn’t,” he said.

But Merck attorney Diane Sullivan painted a different picture, saying Mr. Humeston’s physical condition and other risk factors were to blame, not Vioxx. She said the company had published studies about safety risks and notified the Food and Drug Administration of their findings.

Merck’s scientists were keenly interested in potential safety concerns about the drug, she said, showing jurors a copy of a 2001 e-mail message from company research chief, Edward Scolnick, in which he reacted to a study showing an increased risk of cardiovascular complications for those taking the drug for more than 18 months.

“I was sick at the thought we were doing harm to patients,” Mr. Scolnick wrote.

“For you to believe the plaintiff’s case, you’d have to believe that all these people got together and did something sinister,” Ms. Sullivan told the jury.

Mr. Humeston, 60, of Boise, Idaho, survived and is now suing Merck, saying the company knew the risks posed by the popular arthritis drug but failed to warn consumers adequately.

Holding hands with wife Mary, Mr. Humeston limped into the courthouse yesterday morning, favoring the damaged knee that earned him a Purple Heart and later prompted his doctor to recommend Vioxx.

The trial, one of about 2,475 Vioxx cases pending in New Jersey, is the first one to go to trial since a Texas jury found Merck responsible for the death of a Vioxx user whose widow blamed the drug for his heart arrhythmia. In that case, the jury found Merck to blame and ordered a $253 million award, though that amount is expected to be dramatically reduced because of a Texas law capping punitive damages in civil cases.

The suit was filed in New Jersey — the company’s home state — to prevent Merck from trying to move the case to federal court, which lawyers perceive as less friendly to plaintiffs. Merck also faces about 2,100 lawsuits in federal courts.

Analysts say the company could spend up to $50 billion on settlements and jury awards in Vioxx cases.


Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide